P1.02-04 Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD

Kirsten rat sarcoma (KRAS) is a frequently mutated oncogene in lung adenocarcinoma (LUAD). Recently, KRASG12C was identified to be druggable and KRASG12C inhibitors such as sotorasib and adagrasib had shown great clinical application prospect. However, only KRASG12C inhibitors are clinically used recently, and diverse mechanisms may cause resistance to KRASG12C inhibitors, suggesting that it is urgent to develop new chemotherapeutic strategies based on the biological characteristics of pan-KRASG12 mutant LUAD.